Abstract
In oncology, prevalence (e.g. the number of patients living with a disease), is often assumed synonymous with surviving ever-diagnosed patients. However, with curable cancers, this may overestimate the number of patients with active disease. While counting ever-diagnosed patients may be useful for some purposes, adjusting for cure when estimating prevalence by removing those no longer treated would provide more specific estimates for healthcare planning. The objective here was to demonstrate the impact of cure adjustment in prevalence estimation, using an example of EOC in the United States (US).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
